CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has selected XiFin, Inc. (“XiFin”), a market leader in artificial intelligence (AI)-driven revenue cycle management (RCM) for diagnostic providers, to provide billing and clearinghouse services for the CNSide® Cerebrospinal Fluid (CSF) Assay Platform. The Company expects to commence billing through the XiFin platform during the third quarter of 2026, including submission of the accumulated backlog of previously performed CNSide® tests.
XiFin Empower RCM provides end-to-end revenue cycle infrastructure purpose-built for laboratory-developed tests, including eligibility verification, coding and claims editing, electronic claims submission and clearinghouse connectivity, denials and appeals management, patient billing, and financial reporting. The agreement provides CNSide Diagnostics with scalable, automated billing infrastructure capable of supporting substantially higher test volumes without a proportional increase in administrative cost.
“XiFin is the recognized market leader in diagnostic revenue cycle management, and its technology and expertise will provide a critical piece of infrastructure as we scale CNSide,” said Andrew Sims, Vice President and Chief Financial Officer of Cerenome, Inc. “With our contracted payer coverage now established and growing, XiFin gives us the billing and clearinghouse services to convert testing volume into cash collections. We expect to begin billing with XiFin this quarter, including our backlog, and ramping to our expected volume levels with a platform built for substantial scale.”
The selection of XiFin follows Cerenome’s recent expansion of contracted commercial and Medicare Advantage coverage for CNSide®, and represents the next step in building the commercial infrastructure required to support broad national reimbursement. Together, payer coverage and an automated revenue cycle platform are expected to improve clean claim rates, shorten days sales outstanding, and support the Company’s revenue and profitability objectives.
Cerenome’s Role in Advancing Diagnostic Technology
The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of CNSide® over standard of care has been shown in 12 peer-reviewed publications and prospective multicenter evidence from the FORESEE clinical study, and has been supported by real-world clinical experience.
Since 2020, more than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions, supporting clinical decision-making across academic and community oncology practices nationwide.
This test is available exclusively through CNSide Diagnostics, LLC, as a testing service provided to health care professionals in the U.S.
